WAVE.V Waverley Pharma Inc

Healthcare Biotechnology TSX Venture Exchange
0.0200 CAD
Close of Nov 7, 2026
0.0100 0.0300
Market cap
CAD 1.08M
P/E
-
P/B
1.91x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is WAVE.V undervalued?

Graham number

The Graham number of Waverley Pharma Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Waverley Pharma Inc fundamental analysis

No fundamental analysis for Waverley Pharma Inc yet.

Waverley Pharma Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Waverley Pharma Inc

Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops PARP-1 Inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. In addition, it is involved in the sale of prescription medications, over-the-counter products, and associated pharmacy services. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.

Full company profile